The World Federation of Hemophilia and the Green Cross Corporation signed a three-year agreement on Monday July 25, 2016, to contribute a total of six...
WFH USA is pleased to announce the first installment of Hemophilia Alliance Travel Grants which will begin this year in time for the WFH 2016...
The first case of variant Creutzfeldt-Jakob disease (vCJD) in a patient that is genetically different from all previous confirmed cases has been been reported in...
Over the past decade, the global bleeding disorders community has witnessed great strides in the research of new treatments and methods of care. During the...
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic hepatitis C infection. There have been...
New medications unveiled in the last two years have revolutionized the treatment of hepatitis C (HCV) drastically improving patients’ chances of a cure. The challenge...
For many national hemophilia organizations, the path to improving hemophilia healthcare in their countries comes from the many contributions from both global and regional partners....
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
Over the last few decades, many of the World Federation of Hemophilia (WFH) national member organizations (NMOs) in Latin America have expanded their networks, become...
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...